ATXN2 trinucleotide repeat length correlates with risk of ALS

William Sproviero, Aleksey Shatunova, Daniel Stahl, Maryam Shoai, Wouter van Rhee, Ashley R. Jones, Safa Al-Sarraje, Peter M. Andersen, Nancy M. Bonini, Francesca L. Conforti, Philip Van Damme, Hussein Daoud, Maria Del Mar Amador, Isabella Fog, Monica Forzan, Ben Gastra, Cinzia Gellera, Aaron D. Gitter, John Hardy, Pietro Fratta, Vincenzo La Bella, Isabelle Le Ber, Tim Van Langenhove, Serena Lattante, Yi-Chung Lee, Andrea Malaspina, Vincent Meiningier, Stéphanie Millecam, Richard Orrell, Rosa Rademaker, Wim Robberecht, Guy Rouleau, Owen A. Ross, Francois Salachas, Katie Sidle, Bradley N. Smith, Bing-Wen Soong, Gianni Sorarù, Edor Kabashi, Claire Troakes, Christine van Broeckhoven, Jan H. Veldink, Leonard H. van den Berg, Christopher E. Shawa, John F. Powell, Ammar Al-Chalabi.

*Corresponding author at: Department of Basic and Clinical Neuroscience, King’s College London, Maurice Wohl Clinical Neuroscience Institute, London, United Kingdom.
ARTICLE INFO

Article history:
Received 1 September 2016
Received in revised form 14 November 2016
Accepted 16 November 2016
Available online 24 November 2016

Keywords:
ATXN2
SCA2
ALS
CAG
Expansion
Intermediate expansion
Trinucleotide repeat
Amyotrophic lateral sclerosis
Age of onset
Risk
Exponential risk
Triplet

1. Introduction

Spinocerebellar ataxia type 2 is a trinucleotide repeat disease in which neurodegeneration is a consequence of expansion of a repeated CAG sequence in the ATXN2 gene. All trinucleotide repeat diseases show neurological features and include Huntington’s disease (Paulsen et al., 2014), the spinocerebellar ataxias (Tezenas du Montcel et al., 2014), Friedreich’s ataxia (Koeppen, 2011), fragile X syndrome (Jin and Warren, 2000), myotonic dystrophy (Khoshbakht et al., 2014), and Kennedy’s disease (Yang and Yamamoto, 2014) among others. The mechanism by which the repeated sequence causes disease remains unknown, but a frequently observed feature is a relationship between age of symptom onset, severity of phenotype, and repeat size, with larger repeats associated with younger onset and more severe disease (Nestor and Monckton, 2011).

Intriguingly, trinucleotide repeat expansion in the ATXN2 gene is also a risk factor for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease of upper and lower motor neurons, but this association is only seen for repeats of intermediate size, below the range usually associated with spinocerebellar ataxia (34 repeats or more) but above the normal range (Elden et al., 2010). Such pleiotropy is not seen in other trinucleotide repeat diseases and means that the usually observed relationship between repeat size, age of onset, and severity, might not be straightforward. Here, we investigate the size range defining ALS risk and test the relationship of phenotype with repeat size.

2. Methods

2.1. Unpublished case-control studies

A total of 1474 UK DNA samples of unrelated ALS patients (29 with an affected first degree relative) were collected from a consecutive clinical case series obtained from King’s College Hospital (n = 116), from the Motor Neurone Disease Association DNA Biobank (n = 1051), and from Queen Mary University of London and UCL Institute of Neurology (n = 307). All patients were diagnosed as having definite or probable ALS according to the El Escorial criteria. The DNA samples of 567 neurologically normal controls, matched to patients for gender, age, and geographical region, were obtained from the MRC London Neurodegenerative Diseases Brain Bank, the Institute of Psychiatry, Psychology and Neuroscience (n = 68), from the National Institute for Health Research Mental Health Biomedical Research Centre and the Dementia Unit at South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, King’s College London (n = 306), and from the Motor Neurone Disease Association (n = 193).

A second case-control population-based set was obtained in collaboration with the University Medical Center Utrecht, the Netherlands, with a total of 1328 unrelated ALS cases (23 with a family history in a first degree relative) and 691 neurologically normal controls, matched to patients for gender, age, and geographical region (Liberati et al., 2009). Samples used did not overlap with previous studies of ATXN2 repeat size.

2.2. Standard protocol approvals, registrations, and patient consents

Informed consent was obtained from all included in the study. The study was approved by the Trent Research Ethics Committee 08/HO405/60 and by the Medical Ethics Review Board at the University Medical Center Utrecht 05_067/E.

2.3. Genetic analysis

The DNA samples of 1167 ALS cases and 567 controls were analyzed at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, and DNA samples of 307 ALS cases underwent analysis at the Institute of Neurology, UCL. The ATXN2 CAG trinucleotide repeat region was amplified according to a previously published PCR protocol (Pulst et al., 1996). PCR products at King’s College London were run on an Applied Biosystems 3130xl Genetic Analyzer, and those at UCL on an Applied Biosystems 3730xl Genetic Analyzer. PCR fragments were analyzed using GeneMapper V 4.0 software (Applied Biosystems) to determine CAG trinucleotide repeat size. Electropherogram peaks were sized using GeneScanTM 500 LIZ as reference dye labeled standard. Sequenced samples of known CAG trinucleotide repeat size were used as internal controls for both PCR and GeneScan analysis. PCR products of cases and controls with more than 26 repeats were regenotyped to validate the obtained results.

The DNA samples of 1328 Dutch ALS cases and 691 controls underwent ATXN2 CAG trinucleotide repeat amplification according to a previously reported PCR protocol (Van Damme et al., 2011). PCR products were analyzed using an Applied Biosystems 3130xl.
2.5. Study design, data extraction, and control of bias

This was not an interventional study and therefore was not randomized or blinded. Study selection was restricted to case-control studies published after 1 August 2010, the date of the first reported association between ATXN2 variation and ALS. The exact frequencies of each allele with 24 repeats or greater, and the pooled counts of alleles frequencies with less than 24 repeats were extracted for both PCR and GenScan analysis. PCR products of cases and controls with more than 26 repeats were regenotyped to validate the obtained results.

Samples were also genotyped for C9orf72 expansion as described previously (See Supplementary Material).

2.6. Statistical methods

Relative risks (RRs) were approximated by the odds ratio, generated with corresponding 95% confidence intervals (CIs), by meta-analysis using a Cochran-Mantel-Haenszel chi-square test comparing the case-control counts for a specific allele with the pooled counts of alleles of 23 repeats or fewer across the different published and unpublished studies. RR was then estimated comparing pooled counts of risk alleles with counts of alleles of 23 repeats or fewer. Where a cell contained zero observations, a continuity correction of 0.5 was applied. The sample size was considered adequate to measure the effect size since each individual study in the meta-analysis measured the effect, and the addition of further samples would increase power further. We assumed that all studies were estimating the same common effect and estimates varied only because of chance differences in sampling patients. To assess our assumption, heterogeneity between studies was estimated using the I² statistic (% of variability due to between-study heterogeneity) and Cochrane’s Q-test of heterogeneity. I² > 50% or p < 0.05 for the Q-test were taken as indicative of significant heterogeneity. We used a fixed effects model following the assumption that all studies had a common genetic effect and that specific findings of each study were due to random sampling. However, to control for any possible difference across studies, the fixed effect model RR estimates at each threshold were compared with RR estimates assessed using a random effects model. A sensitivity analysis, leaving out one study at a time, was performed to test the robustness of the meta-analysis and assess the influence of individual studies on the overall result for each allele. Possible sources of heterogeneity across studies were explored using subgroup analysis using source of the control group (population based vs. nonpopulation based) and geographic location (China, Europe, Turkey, USA) as covariates. Meta-regression was used to further investigate differences between population-based and nonpopulation-based subgroups. Funnel plots were generated for each intermediate repeat allele to analyze the intervention effect from individual studies against study size. A resulting p < 0.05 was considered as indicative of the presence of small-study effects. Correlation between age at onset and the CAG trinucleotide repeat size of individual studies against study size.
length of risk alleles was tested in the new British and Dutch ALS cases, and in published data sets for which age at onset data were available. Two-tailed Fisher exact tests were used to test for differences in demographic and clinical characteristics of patients by ATXN2 repeat size. ANOVA was used to compare ages at onset for different repeat sizes, as well as by using SNPs rs695871 and rs695872, previously shown to associate with age of onset. Kaplan-Meier survival analysis and a log-rank test were used to compare survival time between groups. We compared the fit of an exponential model with the fit of a linear model using Akaike information criteria and Bayesian information criteria. Comparison of model values for either measure can be used to assess fit provided the values differ by more than 10. The model with the larger value has less support (Burnham and Anderson, 2002; Raftery, 1995). Meta-analyses were performed using STATA version 12.0 (Stata Corp, College Station, TX, USA). Chi-square tests, ANOVA, and Kaplan-Meier survival analysis were performed using SPSS statistical package version 22 (IBM, Chicago, IL, USA). R language (http://www.R-project.org) was used to test the hypothesis that the relationship between ATXN2 CAG repeat length and ALS risk fitted an exponential model.

3. Results

ATXN2 trinucleotide CAG repeats were analyzed in 1474 ALS cases and 567 neurologically normal controls from the UK and in 1328 ALS cases and 691 neurologically normal controls from the Netherlands. The distribution of allele frequencies is shown in Fig. 1.

All cases were tested for the copresence of ATXN2 intermediate expansions and C9orf72 expansion. Six patients (2 UK, 4 Dutch) had intermediate ATXN2 expansion and pathological expansion of C9orf72. Exclusion of these patients from analyses did not change the overall findings.

Based on literature searches (Fig. 2), we identified all known studies examining ATXN2 repeat expansion in ALS, contacting authors for raw data where necessary, and including studies for analysis based on strict criteria (Supplementary Table 1). Studies passing inclusion criteria (Conforti et al., 2012; Corrado et al., 2011; Daoud et al., 2011; Elden et al., 2010; Gellera et al., 2012; Gispert et al., 2012; Lahut et al., 2012; Lattante et al., 2014; Lee et al., 2011; Liu et al., 2013; Lu et al., 2015; Ross et al., 2011; Soong et al., 2014; Soraru et al., 2011; Van Damme et al., 2011; Van Langenhove et al., 2012) and the 2 novel datasets were used. One Chinese dataset (Chen et al., 2011) was excluded because the authors were unable to provide information on the control group. We excluded studies that might show bias according to the Newcastle-Ottawa Scale criteria (Supplementary Table 2), leaving a total of 15 studies for meta-analysis, comprising 10,888 cases and 15,463 controls (Supplementary Fig. 1). The allele counts of pooled alleles <24 repeats and of each allele with 24 trinucleotide repeats or greater are reported in Supplementary Table 3. No evidence of small-study effect was found in any of the primary analysis studies (data not shown), although we acknowledge that the Funnel plots are not independent of each other.

We first established the definitive size range ascribing risk for ALS, investigating each allele from 24 repeats to 34 repeats by using a fixed effects approach (Supplementary Table 4). The exclusion of the study published by Liu et al. (2013) from analysis of the RR conferred by the 30 repeat allele lowered the initial significant heterogeneity ($I^2 = 48.8\%$, heterogeneity $p = 0.02$) to an overall $I^2$ value of 0% (heterogeneity $p = 0.51$) but did not influence the overall RR estimate. No study exclusion could explain the significant heterogeneity present in the analysis of the 24 repeat allele. No other studies had any effect on heterogeneity or

Fig. 2. Flow chart of study selection according to the PRISMA protocol. Thirteen previously published studies were selected for analysis, 7 from Europe (Conforti et al., 2012; Corrado et al., 2011; Daoud et al., 2011; Gispert et al., 2012; Lattante et al., 2014; Van Damme et al., 2011; Van Langenhove et al., 2012), 3 studies of Han Chinese (2 from China [Liu et al., 2013; Lu et al., 2015] and 1 from Taiwan [Soong et al., 2014]), 1 from Turkey (Lahut et al., 2012), and 2 studies from the USA (Elden et al., 2010; Ross et al., 2011).

RR estimates, including 2 studies that used young controls below the age of risk (Corrado et al., 2011; Elden et al., 2010), and there was no effect of ancestral background of the population studied.
Using a random effects model did not change the findings (Supplementary Table 5).

We found that alleles with 29–33 repeats were associated with ALS (Fig. 3). A meta-analysis of the pooled counts of the risk alleles showed a RR of ALS of 3.06, 95% CI 2.37–3.94, p = 6 × 10^{-18} (Fig. 4). We performed a sensitivity analysis, reintroducing the 3 studies excluded for risk of bias, which did not affect the results (data not shown).

In investigating the effect size of each allele, we found that the risk increased exponentially with length for alleles of 29–32 repeats (R² = 0.91 [95% CI 0.82, 0.99], p = 0.0002; Fig. 5), only dropping off at the boundary for risk of spinocerebellar ataxia type 2, at 33 repeats. This is surprising and has not been reported for any trinucleotide repeat disease. The goodness-of-fit of the exponential model was compared with the fit of a linear model. The exponential model gave a better fit based on Aikake information criteria and Bayesian information criteria criteria (Supplementary Table 6).

Next, we tested the relationship between repeat length and age of ALS onset in the 4 different populations for which data were available. In keeping with previous findings, and in contrast to trinucleotide repeat diseases, we found no evidence for such a relationship (UK [n = 17] age at onset-repeat length regression, p = 0.90; the Netherlands [n = 37] age at onset-repeat length regression, p = 0.08; Belgium [Van Damme et al., 2011; n = 25] age at onset-repeat length regression, p = 0.83; France [Lattante et al., 2014; n = 33] age at onset-repeat length regression, p = 0.49; Flanders-Belgian [Van Langenhove et al., 2012; n = 4] age at onset-repeat length regression, p = 0.60; overall age at onset-repeat length regression, p = 0.14). Nor were there any associations when SNPs rs695871 and rs695872, previously shown to associate with the age of onset, were tested.

We also assessed differences in demographic and clinical characteristics between patients with CAG repeats ≥29 and patients with CAG repeats ≥29 in both British and Dutch cohorts. No significant difference was found in gender, age at onset, or site of onset (Supplementary Table 7). No significant difference in survival was detected by Kaplan-Meier analysis in either the British (p-value = 0.87) or Dutch (p-value = 0.31) cohorts.

**4. Discussion**

We have found the risk range for ATXN2 trinucleotide repeat alleles in ALS is 29–33. An unexpected and important finding is that the risk of ALS increases exponentially with allele repeat size until the border with spinocerebellar ataxia risk, even though the age of onset does not change. This may appear surprising but is entirely consistent with current hypotheses of ALS causation, in which the odds ratio conferred by genetic variants and age of onset of first symptoms are not correlated, even within the same family (e.g., TARDBP, FUS; Abel et al., 2012; Al-Chalabi and Hardiman, 2013; van Rhenen et al., 2016). Our confidence in the finding of an exponential increase in risk is high because this is the largest study of ATXN2 alleles and ALS, our findings overall are consistent with previous studies, and 4 different European populations gave identical results for the relationship of age of onset with trinucleotide allele repeat size. Furthermore, an exponential fit is strongly supported statistically over a linear change in risk. The fact the risk drops off at 33 repeats can be interpreted as a dilution in the case ascertainment, since a large proportion of people with 33 repeats would develop spinocerebellar ataxia (Fernandez et al., 2000) rather than ALS, but we have ascertained on disease state rather than repeat size. To ascertain repeat size, we used a method previously reported to include unrelated PCR products in the critical range of the gel (Pulst et al., 1996). To overcome this limitation, we genotyped all samples twice.

The trinucleotide repeat size range we found associated with risk of ALS overlapped with but was larger than previously reported ranges, (probably because the increased sample size improved our statistical power), and has implications for genetic counseling of individuals carrying intermediate size repeats. Two published meta-analyses, one of 12 and another of 13 studies, reported significant association with ALS for pooled analyses of ATXN2 alleles greater than 30 trinucleotide repeats, a finding that remained significant when restricted to alleles sized between 30 and 33 repeats (Laffita-Mesa et al., 2012; Wang et al., 2014). Another meta-analysis of 9 studies found that individual ATXN2 allele frequencies of 31, 32, and 33 repeats were significantly higher in ALS cases than in controls (Neuenschwander et al., 2014).
It has been suggested that shorter intermediate repeats may be protective for ALS (Neuenschwander et al., 2014). Our data are consistent with this possibility, and indeed for alleles of 27 repeats, show a significant protective effect (Fig. 5, Supplementary Table 4). Previous studies of the ATXN2 repeat length in ALS have not shown a relationship with age of onset (Laffita-Mesa et al., 2012; Neuenschwander et al., 2014; Wang et al., 2014). In this study, 5 populations comprising 5703 cases of the 10,888 individuals studied had age of onset data available. Despite this limitation in numbers, there is unlikely to be a major effect of allele size on the age of onset for ALS. A recent study reported a modification effect of ATXN2 intermediate length repeats on ALS survival for those with 31 or more repeats (Chiò et al., 2015). We did not replicate this finding.

The mechanism by which expanded trinucleotide repeats cause disease does not appear to be the same for all such diseases, even though all trinucleotide repeat expansions result in neurological dysfunction. In some cases, there is a loss of function, for example through hypermethylation (Jin and Warren, 2000), whereas in others, there is a toxic gain of function, for example through aggregation following protein misfolding (Kayatekin et al., 2014). For toxic products of affected genes, larger expansions are likely to result in increased toxicity, and since the products are present from birth, an earlier age of onset or more severe phenotype is the likely outcome of larger repeat sizes. Here, we can add a third outcome of larger repeats: that the risk of disease increases. This can be explained within the recently proposed multistep model of ALS if the toxic effect of intermediate expansions is one of the steps required for ALS to develop, and the toxic effect shows a correlation with repeat size (Al-Chalabi et al., 2014). It also allows for the possibility of oligogenic inheritance, where multiple genetic risk factors act in concert to cause ALS. The mechanism by which this might happen without a concomitant reduction in age of onset remains to be determined. A possible explanation lies in the existence of CAA interruptions to the CAG trinucleotide repeat by direct sequencing (Yu et al., 2011). Thus the interruptions can modify phenotype, and...
Fig. 4. Forest plot of the relative risk of ALS for ATXN2 alleles with 29–33 trinucleotide repeats. UK = new UK data, NL = new Dutch data. Fifteen studies at low risk of bias were included. Fixed effects methods were used to estimate the relative risk. No heterogeneity was observed (p-value of heterogeneity > 0.05). Abbreviation: ALS, amyotrophic lateral sclerosis.

Fig. 5. Plot of the relative risk for each ATXN2 allele (25–32 repeats). The distribution of the relative risk estimates of alleles of between 25 and 32 CAG trinucleotide repeats obtained from the 15 low bias studies fitted an exponential curve well, showing an exponential growth in relative risk, surpassing the threshold for significant association for alleles of size 29–32 (R² = 0.91 [95% CI 0.82, 0.99], p < 0.0002). The relative risk estimate of the 24 repeat allele was excluded because of a large unidentified heterogeneity across studies. Including this allele, however, did not significantly change the curve fit. Black bars indicate the 95% CI of the relative risk estimates. The red line indicates no effect. Abbreviation: CI, confidence interval.
an interaction between repeat length and CAA interruption could underlie ALS risk and the lack of effect on the age of onset. Furthermore, although both Dutch and UK cohorts had individuals with more than 33 repeats, they did not have spinocerebellar ataxia, a finding which might be related to CAA interruptions.

5. Conclusion

Our study increases the breadth of known effects of trinucleotide repeat expansion size, adding disease risk to the existing correlations with age of onset and disease severity. Thus, the main finding presented here is that trinucleotide repeat expansion in the ATXN2 gene in the size range exclusively for ALS risk represents an exponentially increasing risk for each additional repeat.

Disclosure statement

The authors have no conflicts of interest to disclose.

Acknowledgements

This work was supported by the EU Joint Programme for Neurodegenerative Disease Research projects SOPHIA, STRENGTH, and NETCALS. Christopher E. Shaw, Ammar Al-Chalabi, and Daniel Stahl receive salary support from the National Institute for Health Research Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King’s College London. Philip Van Damme holds a senior clinical investigatorship of FWO-Flanders and is supported by the Belgian ALS ligue. William Sproviero, Richard Orrell, John Hardy, and Maryam Shoai are funded by the MND Association. The views expressed are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health, the Belgian ALS ligue, or the MND Association. The work leading up to this publication was funded by the European Community’s Health Seventh Framework Programme (FP7/2007–2013; grant agreement number 259867, and the Programme d’investissement d’avenir [IHU-A-ICM]). Samples used in this research were in part obtained from the UK National DNA Bank for MND Research, funded by the MND Association and the Wellcome Trust, and by University Medical Center Utrecht. The authors would like to thank people with MND and their families for their participation in this project. They also acknowledge sample management undertaken by Biobanking Solutions funded by the Medical Research Council at the Centre for Integrated Genomic Medical Research, University of Manchester.

The associations which funded ATXN2 analyses in the French ALS/control cohorts are: the Association pour la Recherche sur la Sclérose latérale amyotrophique et autres maladies du motoneurone (ARSla, France, contract R13132DD) and the Association française contre les myopathies (AFM, France, contract R11038DD). The research at the Antwerp site was in part funded by the Belgian Science Policy Office Interuniversity Attraction Poles program, the Flemish Government initiated Attraction Program Methusalem, the Research Foundation Flanders, and the University of Antwerp Research Fund; Belgium. The study published by Sorarù et al. (2011) was funded by Telethon Biobank (GTB12001D). The authors also thank the authors of the “Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis” Neurology, 2012 paper for their collaboration (Conforti et al., 2012) and all the contacted authors who shared their data.

Author’s contributions: All authors contributed to the final manuscript. William Sproviero, Aleksey Shatunov, and Ammar Al-Chalabi contributed to the literature search, figures, study design, data collection, data analysis, data interpretation, writing, and revision of the manuscript. William Sproviero, Aleksey Shatunov, Maryam Shoai, and Wouter van Rheenen did the genotyping and data analysis. Daniel Stahl contributed to data interpretation, writing, and revision of the manuscript. Ashley R Jones, Ben Gaaster, and Isabella Foug contributed to the revision of the manuscript and all authors approved the manuscript. Christopher E. Shaw, Bradley N Smith, John F Powell, Safa Al-Sarraj, Andrea Malaspina, Pietro Fratta, Katie Sidle, John Hardy, Richard Orrell, Claire Troakes, Jan H. Veldink, and Leonard H. van den Berg contributed samples or genotypes or both. Peter M. Andersen, Nancy M. Bonini, Francesca L. Conforti, Philip Van Damme, Hussein Daoud, Maria Del Mar Amador, Monica Forzan, Cinzia Gellera, Aaron D. Gitler, Edor Kabashi, Vincenzo La Bella, Isabelle Le Ber, Tim Van Langenhove, Serena Lattante, Yi-Chung Lee, Andrea Malaspina, Vincent Meiningier, Stéphanie Millicamps, Rosa Rademakers, Wim Robberecht, Guy Rouleau, Owen A. Ross, Francois Salachas, Bing-Wen Soong, Gianni Sorarù, Giovanni Stevaní, and Christine van Broeckhoven contributed genotypes data or information not reported in the manuscripts included in the systematic review and meta-analysis.

Appendix A. Supplementary data

Supplementary data associated with this article can be found in the online version, at http://dx.doi.org/10.1016/j.neurobiolaging.2016.11.010.

References

Abel, O., Powell, J.F., Andersen, P.M., Al-Chalabi, A., 2012. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 33, 1345–1351.
Al-Chalabi, A., Calvo, A., Chio, A., Colombi, S., Ellis, C.M., Hardiman, O., Heverin, M., Howard, R.S., Huusius, M.H., Keren, N., Leigh, P.N., Mazzini, L., Mora, G., Orrell, R.M., Rooney, I., Scott, E.M., Scott, W.J., Seelen, M., Shaw, C.E., Sidle, K.S., Swingler, R., Tsuda, M., Veldink, J.H., Visser, A.E., van den Berg, L.H., Pearce, N., 2014. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 13, 1108–1113.
Al-Chalabi, A., Hardiman, O., 2013. The epidemiology of ALS: a conspiracy of genes, environmental and time. Nat. Rev. Neurol. 9, 617–628.
Burnham, K.P., Anderson, D.R., 2002. Model Selection and Multimodel Inference: A Practical Information-theoretic Approach. Springer-Verlag, New York.
Chen, Y., Huang, R., Yang, Y., Chen, K., Song, W., Pan, P., Li, J., Shang, H.F., 2011. Ataxin-2 intermediate-length polyglutamine: a possible risk factor for Chinese patients with amyotrophic lateral sclerosis. Neurobiol. Aging 32, 1925–1933.
Chib, A., Calvo, A., Moglia, C., Canosa, A., Brunetti, M., Barberis, M., Restagno, G., Conte, A., Bisogno, G., Maranghi, G., Moncada, A., Lattante, S., Zollino, M., Sabatelli, M., Bagagetti, A., Corrado, L., Mora, G., Bersano, E., Mazzini, L., L’Alfonso, S., PARALS. 2015. ATXN2 polyQ intermediate repeats are a modifier of ALS survival. Neurology 84, 251–258.
Conforti, F.L., Spataro, R., Sproviero, W., Mazzei, R., Cavalcanti, F., Condino, F., Simone, I.L., Logroscino, G., Patucci, A., Magariello, A., Muglia, M., Rodolico, C., Valentino, P., Bono, F., Colletti, T., Monsurro ,M.R., Gambardella, A., La Bella, V., 2012. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis. Neurology 79, 2315–2320.
Corrado, L., Mazzini, L., Oggiioni, G.D., Luciano, B., Godi, M., Brusco, A., D’Alfonso, S., 2011. ATXN-2 CAG repeat expansions are interrupted in ALS patients. Hum. Genet. 130, 575–586.
Daudet, H., Belzil, Y., Martins, S., Sabbagh, M., Provencher, P., Lacomblez, L., Meiningier, V., Camu, W., Dupré, N., Dion, P.A., Rouleau, G.A., 2011. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis. Arch. Neurol. 68, 739–742.
Elden, A.C., Kim, H.J., Hart, M.P., Chen-Plotkin, A.S., Johnson, B.S., Fang, X., Armakola, M., Geser, F., Greene, R., Lu, M.M., Padmanabhan, A., Clay-Dcone, F., McCluskey, L., Elman, L., Juhr, D., Gruber, P.J., Rüb, U., Auburger, G., Wagner, J., Meiningier, S., Sorarù, S., Lee, A., Morris, R.H., Monsurro, M.R., Valsasina, B., Tatei, T., 2012. Ataxin-1 and ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069–1075.
Fernandez, M., McClain, M.E., Martinez, R.A., Snow, K., Lipe, H., Ravits, J., Bird, T.D., La Spada, A.R., 2000. Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology 55, 569–572.
Geller, C., Ticozzi, N., Pensato, V., Nanetti, L., Castucci, A., Castelli, B., Lauria, G., Taroni, F., Silani, V., Mariotti, C., 2012. ATXN2CAG-repeat length in Italian patients with amyotrophic lateral sclerosis: risk factor or variant phenotype? Implication for genetic testing and counseling. Neurobiol. Aging 33, 1847.
Gispert, S., Kurz, A., Waibel, S., Bauer, F., Llepet, I., Geisen, C., Gitler, A.D., Becker, T., Weber, M., Berg, D., Andersen, P.M., Krüger, R., Riess, O., Ludolph, A.C., Auburger, G., 2012. The modulation of Amyotrophic Lateral Sclerosis risk by
axatin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol. Dis. 56, 356–361.

Huisman, M.H., de Jong, S.W., van Doormaal, P.T., Weinreich, S.S., Schelhaas, H.J., van der Kooi, A.J., de Visser, M., Veldink, J.H., van den Berg, L.H., 2011. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J. Neurol. Neurosurg. Psychiatry 82, 1165–1170.

Jin, F.P., Warren, S.T., 2005. Understanding the molecular basis of fragile X syndrome. Mol. Genet. Hum. Genet. 70, 1021–1032.

Kateman, C., Matallak, K.E., Hesse, W.R., Guan, Y., Chakrabarti, S., Russ, J., Wanler, E.E., Shah, J.V., Lindquist, S., 2014. Prion-like protein sequestration and suppress the toxicity of huntingtin exon 1. Proc. Natl. Acad. Sci. U. S. A. 111, 12085–12090.

Khoshtbakht, R., Soltanazadeh, A., Zamani, B., Abdi, S., Garagolzi, K., Kahrizi, K., Khoshtbakht, R., Nafissi, S., 2014. Correlation between distribution of muscle weakness, electrophysiological findings and CTG expansion in myotonic dystrophy. J. Clin. Neurosci. 21, 1123–1126.

Kim, J.M., Hong, S., Kim, G.P., Choi, Y.J., Kim, Y.K., Park, S.S., Kim, S.M., Jeon, B.S., 2007. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. Arch. Neurol. 64, 1510–1518.

Koeppen, A.H., 2011. Friedreich’s ataxia: pathology, pathogenesis, and molecular genetics. J. Neurol. Sci. 303, 1–12.

Laffita-Mesa, J.M., Velázquez-Pérez, L.C., Santos Falcón, N., Cruz-Marínó, T., González Zaldivar, Y., Vázquez Mojena, Y., Alamogor-Getay, D., Alamogor Mederos, L.E., Rodríguez Labrada, R., 2012. Unexpanded and intermediate CAG polymorphisms at the SCA2 locus (ATXN2) in the Cuban population: evidence about the origin of expanded SCA2 alleles. Eur. J. Hum. Genet. 20, 41–49.

Lahut, S., Omir, O., Uyan, O., Agım, Z.S., Özoz, A., Parman, Y., Deymeier, F., Olfazer, P., Koç, F., Ozcelik, H., Auburger, G., Başak, A.N., 2012. ATXN2 and its neighbouring gene SH2B3 are associated with increased ALS risk in the Turkish population. PLoS One 7, e42956.

Lattante, S., Millecamps, S., Stevanin, G., Riva-Péchoux, S., Moigné, C., Camuzat, A., Da Barroca, S., Mundwiler, E., Courarch, P., Salachas, F., Hannequin, D., Meiningier, V., Pasquier, F., Seifehan, D., Courratier, P., Danel-Brunaud, V., Bonnet, A.M., Tranchant, C., LeGuennec, E., Brice, A., Le Ber, I., Kabashi, E., French Research Network on FTD and FTD-ALS, 2014. Contribution of ATXN2 intermedia polyQ expansions in a spectrum of neurodegenerative disorders. Neurology 83, 990–995.

Lee, T., Li, Y.R., Ingre, C., Weber, M., Greif, T., Gredal, O., de Carvalho, M., Meyer, T., Tysnes, O.B., Auburger, G., Gispert, S., Bonini, N.M., Andersen, P.M., Gitler, A.D., 2011. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients. Hum. Mol. Genet. 20, 1697–1705.

Leelawat, C., Gillon, P., Farrer, M., Burrell, W.N., de Vries, J., van den Berg, L.H., Veldink, J.H., 2016. Genome-wide association analyses identify new risk variants and SCA2. Neurobiol. Aging 37, 2455–2466.

Li, X., Huang, M., Li, Q., Chen, Y., Zhang, J., Li, X., Yang, L., Su, J., Zeng, Z., Yang, X., Guo, Y., Wang, Y., Wang, Y., Wang, W., 2014. Intermediate-length polyglutamine expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiol. Aging 35, 2378–2385.

Lichtner, P., Rietschel, M., Cichon, S., Nöthen, M.M., Amouyel, P., Tzourio, C., Dartigues, J.F., Leheuguè, J.F., Meyer, T., Scherzer, R., Ophoff, R.A., Staats, K.A., Wiedau-Pazos, M., Lomen-Hoerth, C., Van Deursen, V.M., Trojanowskij, J.O., Elman, L., Mccluskey, L., Basak, A.N., Tunca, H., Hamzeiy, H., Parmentier, T., Richter, S., Pescatori, J., Pfaff, D., Pecot, F., Brandt, T., Fratelli, L., Timmerman, T., Schols, J.M., van den Berg, L.H., 2011. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 10, 852–860.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.

Lichtenstein, P., Wall, S., Berg, C., Hennekens, C., Hennekens, C., Lipworth, L., De Stefani, E., 2003. Prediction of manifest Huntington disease with clinical and imaging markers: a prospective observational study. Lancet Neurol. 2, 618–624.